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Objectives
To assess the impact of highly active antiretroviral therapy (HAART) on rates of change of
antiretroviral treatment among patients co-infected with hepatitis B virus (HBV) and/or hepatitis C
virus (HCV) in the Australian HIV Observational Database (AHOD).
Methods
Analysis was based on 805 of the 2218 patients recruited to the AHOD by March 2003, who had
commenced HAART after 1 January 1997, who had recorded test results for HBV surface antigen and
anti-HCV antibody, and who had follow-up of more than 3 months. The effect of hepatitis co-
infection on the rate of antiretroviral treatment change after commencing HAART was assessed
using a random-effect Poisson regression model.
Results
Among those included in the analyses, the prevalences of HBV and HCV were 4.8% and 12.8%,
respectively. The overall rate of combination antiretroviral treatment change was 0.74 combinations
per year. Factors independently associated with an increased rate of change of combination
antiretroviral treatment were: prior AIDS-defining illness; prior exposure to double combination
antiretroviral therapy; and antiretroviral treatment class. Co-infection with HBV and/or HCV was not
found to be significantly associated with the rate of combination antiretroviral treatment change.
Conclusions
While both HBV and HCV co-infections are relatively common in the AHOD, they do not appear to
be serious impediments to the treatment of HIV-infected patients.
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The use of highly active antiretroviral therapy (HAART) in
Australia since 1996 has dramatically reduced the morbid-
ity and mortality of patients with HIV [1,2]. As the survival
of HIV-infected patients continues to improve, and despite
the obvious success of HAART, the necessity to continue
therapy long term introduces other concerns, such as
treatment-related toxicity and the management of co-
morbid conditions such as chronic viral hepatitis.
HIV is known to impact on the natural history of hepatitis
B virus (HBV) and hepatitis C virus (HCV) disease. There has
been evidence of higher rates of chronic HBV infection
among HIV/HBV co-infected patients and higher HCV viral
loads among those with HIV/HCV co-infection [3]. How-
ever, the impact of HBV and HCV on HIV remains
ambiguous. Several studies have shown no impact of HBV
or HCV co-infection on HIV disease progression [4,5], while
others have shown accelerated HIV disease progression
[6,7]. Although there has been a slightly poorer CD4 count
response in HIV/HCV co-infected patients [4,8], the impact
of HAART on disease progression among patients co-
infected with HBV and/or HCV remains relatively uncertain,
particularly in the presence of treatment-related toxicities.
Hepatotoxicity associated with antiretroviral use has
been shown in several studies to be more common in HIV-
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infected patients co-infected with HCV or HBV, particularly
after initiating antiretroviral treatment [9,10]. The protease
inhibitor (PI) ritonavir and, more recently, nonnucleoside
reverse transcriptase inhibitors (NNRTIs), including nevir-
apine and efavirenz, have been associated with hepato-
toxicity [10]. However, others have found no association
between the use of NNRTIs and hepatotoxicity [11].
The aim of the present study was to assess the impact of
HAART on rates of change of antiretroviral treatment
among patients co-infected with HBV and/or HCV in the
Australian HIV Observational Database (AHOD). In a
previous study [12], we demonstrated the use of rates of
change of antiretroviral therapy to be a useful mid-range
surrogate marker of disease progression, and to be more
long range than conventional markers such as CD4 count
and HIV viral load, but earlier than clinical AIDS-defining
illness or death. This may be a good endpoint for
examining the response to HAART in co-infected patients,
in whom not only would HIV disease progression be
expected to lead to increased rates of antiretroviral
treatment change, but also significant liver toxicity to
treatment would be expected to lead to increased rates of
antiretroviral treatment change.
We also assessed the durability of the first HAART
regimen, and the durability of HAART regimens including
NNRTIs, which have been associated with liver toxicity.
Methods
Patients and data collection
The Australian HIV Observational Database collects data
from 27 sites throughout Australia, including hospitals,
sexual health clinics and general practitioners. Data are
transferred electronically to the National Centre in HIV
Epidemiology and Clinical Research (NCHECR) every 6
months. The following core data variables are collected:
sex, date of birth, date of first positive HIV test result, date
of most recent visit, HIV exposure category, HBV status,
HCV status, CD4 and CD8 T-lymphocyte counts, HIV viral
load counts, antiretroviral and opportunistic infection
prophylaxis treatments, including start and stop dates,
and AIDS-defining illnesses.
To be included in the present study, patients in the AHOD
had to meet the following requirements: (1) initiation of
HAART, defined as a combination of at least three
antiretroviral agents, after 1 January 1997; (2) recorded
test results for both HCV antibodies and HBV surface
antigen (HBsAg); and (3) follow-up of at least 3 months
from baseline, defined as the date the patient commenced
HAART.
Definition of HBV and HCV serological categories
HBV infection was defined as a positive HBV surface
antigen (HBsAg) test, and HCV infection as a positive anti-
HCV antibody test. No distinction was made between
patients being tested for hepatitis before and after initiation
of HAART. Co-infection status was classified as follows:
HBV and HCV negative; HBV positive only; HCV positive
only; and co-infection with HBV and HCV.
Definition of combination change
An antiretroviral treatment change was defined as any
change to a combination, including adding or dropping
treatments, or reinitiating treatments previously received.
In this definition, a treatment interruption of greater than 7
days was also considered a change.
Statistical analyses
For each patient, data were censored at the last date of
follow-up, defined as the most recent of the following
dates: most recent visit date, date of CD4 or viral load
count, or date on which antiretroviral therapy started or
stopped. Individual person-years of follow-up were calcu-
lated as the time between baseline (initiation of HAART)
and the date of last follow-up. Rate of change of
antiretroviral treatment was calculated as the number of
combination changes over the person-years of follow-up.
The effect of hepatitis co-infection on the rate of
antiretroviral treatment change after commencing HAART
was assessed using a random-effect Poisson regression
model, which allowed for the repeated-event nature of the
data [13]. The effect of hepatitis co-infection on time to
changing the first HAART combination was assessed with
Kaplan–Meier survival curves and Cox proportional hazard
models of time to change of first HAART combination.
Covariates tested for inclusion in multivariate models
were sex, age group, HIV exposure category, viral load at
baseline, CD4 cell count at baseline, AIDS-defining illness
prior to baseline, antiretroviral therapy prior to baseline
(none, mono or double), treatment class and calendar year.
Nominal covariates were tested using w2 tests for hetero-
geneity and ordinal covariates using tests for trend.
Missing values were not included when testing ordinal
covariates. Multivariate models were obtained using
forward selection techniques.
In addition, the association between hepatitis co-
infection and time to stopping nevirapine or efavirenz
was examined with Kaplan–Meier survival curves and the
Wilcoxon test statistic.
All statistical analyses were performed using STATA8.0 [14].
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Results
By March 2003, 2218 HIV-positive patients had been
recruited to the AHOD. Of these, 805 met the study
inclusion criteria, having commenced HAART after 1
January 1997, recorded test results for HBsAg and anti-
HCV antibody, and had follow-up of more than 3 months.
The median follow-up overall was 4.1 years, with a total of
3320 person-years.
Thirty-nine patients (4.8%) tested positive for HBsAg
only, 103 patients (12.8%) tested positive for anti-HCV
antibody only, and 15 patients (1.9%) tested positive for
both HBsAg and anti-HCV antibody.
Patient characteristics, by HBV/HCV status, are summar-
ized in Table 1. A greater proportion of those with HCV
only were female (13%), and had an HIV exposure category
of injecting drug use (IDU) [men having sex with men
(MSM) plus IDU, or IDU] (37%), when compared with those
with other HBV/HCV status. Patients co-infected with
either HBV or HCV were slightly younger than those
without HBV or HCV. Approximately 54% of those infected
with HIV only were less than 40 years of age, in
comparison with 67% of those with HBV only, 65% of
those with HCV only, and 87% of those with HBV and HCV.
Rate of change of antiretroviral treatment
The overall mean rate of treatment change after initiating
HAART was 0.73 [95% confidence interval (CI): 0.70–0.77]
per year for those without HBV/HCV co-infection, 0.71
(95% CI: 0.58–0.86) per year for those with HBV, and 0.83
Table 1 Patient characteristics by hepatitis B and C virus status
HBV /HCV HBV1 /HCV HBV /HCV1 HBV1 /HCV1
n % n % n % n %
Overall 648 39 103 15
Sex
Male 605 93.4 37 94.9 90 87.4 15 100
Female 43 6.6 2 5.1 13 12.6 0 0
Age (years)
o30 89 13.7 6 15.4 17 16.5 3 20
30–39 263 40.6 20 51.3 50 48.5 10 66.7
40–49 188 29 11 28.2 30 29.1 1 6.7
501 108 16.7 2 5.1 6 5.8 1 6.7
HIV exposure category
MSM 467 74 25 65.8 45 44 8 53.3
MSM and IDU 22 3.5 4 10.5 21 20 5 33.3
IDU 7 1.1 0 0 16 15 0 0
Heterosexual 69 10.9 5 13.2 7 7 0 0
Blood 3 0.5 1 2.6 1 1 2 13.3
Other and NR 63 10 3 7.9 10 10 0 0
CD4 count (cells/mL)
o200 150 23.2 9 23.1 27 26.2 6 40
200–350 147 22.7 9 23.1 19 18.5 2 13.3
3501 241 37.2 14 35.9 31 30.1 2 13.3
NR 110 17 7 18 26 25.2 5 33.3
HIV viral load (HIV-1 RNA copies/mL)
o10 000 131 20.2 8 20.5 14 13.6 2 13.3
10 000–50 000 137 21.1 12 30.8 18 17.5 2 13.3
50 0001 269 41.5 12 30.8 46 44.7 6 40
NR 111 17.1 7 18 25 24.3 5 33.3
Previous AIDS-defining illness
No 560 86.4 31 79.5 85 82.5 12 80
Yes 88 13.6 8 20.5 18 17.5 3 20
Previous ART
None 431 66.5 27 69.2 62 60.2 12 80
Mono 50 7.7 1 2.6 11 10.7 0 0
Double 167 25.8 11 28.2 30 29.1 3 20
Year HAART commenced
1997–1999 534 82.4 30 76.9 80 77.7 12 80
2000–2002 114 17.6 9 23.1 23 22.3 3 20
Co-infection status: HBV and HCV negative (HBV /HCV ); HBV positive only (HBV1 /HCV ); HCV positive only (HBV /HCV1 ); and co-infection with
HBV and HCV (HBV1 /HCV1 ).
MSM, men who have sex with men; IDU, injecting drug user; NR, not recorded; ART, antiretroviral therapy; HAART, highly active antiretroviral therapy.
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per year for those with HCV (95% CI: 0.75–0.93) and
for those with both HBV and HCV co-infection (95% CI:
0.59–1.12).
Rate of change of antiretroviral treatment after com-
mencing HAART was not associated with co-infection
status (P5 0.40). Table 2 presents factors associated with
Table 2 Factors associated with the rate of combination antiretroviral treatment change after commencing highly active antiretroviral therapy
(HAART)
Univariate Multivarative
n FU Count Rate IRR 95% CI P Overall P * IRR 95%CI P Overall P *
Overall 805 3318 2473 0.745
Hepatitis status
HBV–/HCV– 648 2707 1982 0.732
HBV1 /HCV– 39 147 104 0.709 0.91 0.65–1.28 0.593 0.95 0.70–1.29 0.740
HBV–/HCV1 103 416 346 0.833 1.12 0.91–1.38 0.282 1.14 0.95–1.37 0.157
HBV1 /HCV1 15 50 41 0.828 1.39 0.82–2.33 0.218 0.396 1.40 0.88–2.23 0.150 0.249
Sex
Male 747 3073 2223 0.723
Female 58 245 250 1.019 1.30 1.01–1.68 0.043 0.043 1.16 0.92–1.46 0.204 0.204
Age (years)
o 30 115 439 372 0.846
30–39 343 1414 1009 0.713 0.91 0.74–1.13 0.388 0.88 0.73–1.07 0.200
40–49 230 974 696 0.714 0.91 0.72–1.14 0.398 0.85 0.69–1.04 0.109
501 117 490 396 0.808 1.03 0.80–1.34 0.805 0.770 0.99 0.79–1.25 0.960 0.894
HIV exposure
MSM 545 2263 1661 0.734
Other 239 1056 812 0.769 1.02 0.88–1.18 0.825 0.825 1.04 0.91–1.18 0.603 0.603
CD4 at baseline (cells/mL)
o 200 192 771 617 0.801
200–350 177 672 472 0.702 0.88 0.71–1.08 0.221 1.04 0.86–1.26 0.677
3501 288 1194 838 0.702 0.88 0.74–1.06 0.186 0.96 0.81–1.14 0.618
NR 148 681 546 0.802 0.98 0.80–1.22 0.885 0.220 1.03 0.85–1.24 0.798 0.537
HIV viral load at baseline
(HIV-1 RNA copies/mL)
o 10 000 155 633 491 0.775
10 000–50 000 169 732 480 0.656 0.84 0.67–1.04 0.117 0.95 0.78–1.16 0.615
50 0001 333 1275 941 0.738 0.97 0.80–1.17 0.737 1.09 0.91–1.31 0.326
NR 148 679 561 0.827 1.04 0.84–1.30 0.701 0.975 1.11 0.91–1.35 0.307 0.164
Previous ADI
No 688 2817 1979 0.702
Yes 117 501 494 0.986 1.41 1.17–1.69 0.000 0.000 1.34 1.14–1.58 0.001 0.001
Previous ART
None 532 2104 1350 0.642
Mono 62 284 251 0.885 1.36 1.06–1.74 0.015 1.24 0.99–1.55 0.057
Double 211 931 872 0.937 1.43 1.23–1.66 0.000 0.000 1.29 1.12–1.48 0.000 0.000
Drug class
PI-based HAART
(excludes NNRTI) 1189 1298 934 0.720
NNRTI-based HAART
(excludes PI) 892 1250 567 0.454 0.67 0.59–0.76 0.000 0.70 0.62–0.79 0.000
NNRTI/PI HAART combination 221 175 178 1.018 1.30 1.06–1.60 0.012 1.29 1.05–1.57 0.013
Mono or double 426 176 370 2.099 2.61 2.22–3.07 0.000 2.69 2.29–3.14 0.000
None 608 420 424 1.010 1.16 1.00–1.34 0.046 0.000 1.26 1.09–1.45 0.002 0.000
Time period
1997/1998 530 632 563 0.891
1999 656 592 467 0.789 0.91 0.80–1.03 0.135 0.92 0.81–1.04 0.175
2000 727 683 525 0.769 0.89 0.79–1.01 0.072 0.92 0.81–1.04 0.181
2001 739 689 461 0.669 0.78 0.69–0.89 0.000 0.78 0.69–0.89 0.000
2002/03 706 722 457 0.633 0.73 0.64–0.83 0.000 0.000 0.72 0.63–0.83 0.000 0.000
*P-values reported for test of homogeneity in nominal covariates and test for trend in ordinal covariates. Patients with data not recorded were not included
when testing trend.
Co-infection status: HBV and HCV negative (HBV /HCV ); HBV positive only (HBV1 /HCV ); HCV positive only (HBV /HCV1 ); and co-infection with
HBV and HCV (HBV1 /HCV1 ).
FU, follow-up; IRR, incidence rate ratio; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; MSM, men who have sex with men; NR, not
recorded; ADI, AIDS-defining illness; ART, antiretroviral therapy; HAART, highly active antiretroviral therapy; NNRTI, nonnucleoside reverse transcriptase
inhibitor; PI, protease inhibitor.
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the rate of treatment change. In univariate analysis, rates of
change were significantly associated with sex (P5 0.043),
AIDS-defining illness prior to initiating HAART (Po0.001),
and exposure to antiretroviral therapy prior to commen-
cing HAART (Po0.001). Antiretroviral treatment class was
also found to be associated with the rate of treatment
change (Po0.001), as well as the calendar year (Po0.001).
Age, HIV exposure category, CD4 at baseline and RNA at
baseline were not significantly associated with rate of
treatment change.
In multivariate analysis, AIDS-defining illness [inci-
dence rate ratio (IRR)5 1.34; Po0.001] and exposure to
double therapy prior to initiating HAART (IRR5 1.29;
Po0.001) continued to be associated with increased rates
of treatment change. Class of treatment combination also
remained significantly associated with rates of change.
Combinations that included a NNRTI, but not a PI, were
associated with a slower rate of change than combinations
that did not include a NNRTI (IRR5 0.70; Po0.001);
combinations that included both a NNRTI and a PI were
associated with a faster rate of change than combinations
that did not include a NNRTI (IRR5 1.29; P5 0.013); and
mono or double therapies, and no therapy, were associated
with increased rates of combination change (IRR5 2.69;
Po0.001 and IRR5 1.26; P5 0.002, respectively). During
more recent time periods, particularly from 2001 onwards,
the rates of combination change were also significantly
slower compared with earlier years (Po0.001).
Post hoc analysis examined the association between
ritonavir-boosted combinations and rates of treatment
change. Combinations including stavudine and didanosine
and their association with rates of change were also
analysed. Results showed that treatment combinations that
included ritonavir with at least one other PI did not differ
significantly from other PI-containing regimens (P5 0.92).
However, combinations that included stavudine and/or
didanosine demonstrated a significantly faster rate of
treatment change compared with combinations excluding
these two antiretrovirals (P5 0.024).
Time to first treatment change
The median durations spent on first HAART combinations,
by co-infection status, are shown in Fig. 1. Overall, the
median duration on first HAART combination was 482
days for those without HBVor HCV, 686 days for those with
HBV alone, 398 days for those with HCV alone, and 172
days for those with HBV and HCV co-infection.
Time to first treatment change after commencing HAART
was not significantly associated with co-infection status
(P5 0.51). The hazard ratios (HRs) from the Cox propor-
tional hazard model for time to first treatment change after
commencing HAART are presented in Table 3. In univariate
analysis, AIDS-defining illness prior to commencing
HAART, and exposure to double therapy prior to commen-
cing HAART, were associated with a faster time to first
treatment change (P5 0.041 and P5 0.009, respectively).
Combinations that included a NNRTI, but not a PI, were
associated with a slower time to change than combinations
that did not include a NNRTI (HR5 0.63; Po0.001). Age,
sex, HIV exposure category, CD4 at baseline, RNA at
baseline, and year of first change were not significantly
associated with time to first treatment change.
In multivariate analysis, exposure to double therapy
prior to initiating HAART (HR5 1.25; P5 0.014) was found
to be independently associated with a faster time to
combination change. In addition, combinations that
included a NNRTI, but not a PI, remained significantly
associated with a slower time to change than combinations
that did not include a NNRTI (HR5 0.64; Po0.001).
Time to stopping nevirapine or efavirenz
Of the 805 patients who met the study inclusion criteria, 611
commenced a HAART combination that included nevirapine
or efavirenz at some stage during the follow-up period.
Overall, the median time between commencing and stopping
either nevirapine or efavirenz was 1344 days. The median
durations spent on treatments that included nevirapine or
efavirenz, by co-infection status, are shown in Fig. 2. Time
to stopping nevirapine or efavirenz was not associated with
hepatitis co-infection (P5 0.86, Wilcoxon test).
Discussion
In the AHOD, the prevalences of HBV and HCV were 4.8%
and 12.8%, respectively. Among the patients who were
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Fig. 1 Time to first antiretroviral treatment change after commen-
cing highly active antiretroviral therapy (HAART), by hepatitis B and
C virus co-infection status.
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included in this study (those who commenced HAART after
1997 and had been tested for HBV and HCV infection), the
overall rate of combination antiretroviral treatment change
was 0.74 combinations per year, varying among the co-
infected groups. The rate of combination antiretroviral
treatment change was 0.73 per year among patients
infected only with HIV, 0.71 per year among HIV/HBV
co-infected patients, and 0.83 per year among HIV/HCV
co-infected patients and HIV/HBV/HCV co-infected
patients.
Table 3 Time to first antiretroviral combination change after commencing highly active antiretroviral therapy
Non-events Events Univariate Multivariate
n % n % HR 95% CI P P * HR 95% CI P P *
Overall 173 632
Hepatitis status
HBV –/HCV – 143 82.7 505 79.9
HBV1 /HCV – 7 4.1 32 5.1 1.02 0.72–1.46 0.901 1.02 0.71–1.46 0.925
HBV –/HCV1 21 12.1 82 13 1.11 0.88–1.40 0.377 1.13 0.90–1.43 0.293
HBV1 /HCV1 2 0.2 13 2.1 1.44 0.83–2.50 0.196 0.507 1.41 0.81–2.45 0.224 0.486
Sex
Female 17 9.8 41 6.5
Male 156 90.2 591 93.5 0.99 0.72–1.35 0.932 0.932 0.94 0.68–1.29 0.692 0.692
Age (years)
o 30 26 15 89 14.1
30–39 80 46.2 263 41.6 0.80 0.63–1.02 0.075 0.79 0.62–1.01 0.057
40–49 49 28.3 181 28.6 0.84 0.65–1.08 0.180 0.80 0.62–1.04 0.098
501 18 10.4 99 15.7 1.08 0.81–1.43 0.613 0.378 0.99 0.74–1.33 0.972 0.761
HIV exposure category
MSM 103 59.5 442 69.9
Other 70 40.5 190 30.1 0.87 0.74–1.04 0.121 0.121 0.88 0.74–1.04 0.131 0.131
CD4 count at baseline
o 200 41 23.7 151 23.9
200–350 53 30.6 124 19.6 0.86 0.68–1.09 0.214 0.96 0.76–1.23 0.764
3501 58 33.5 230 36.4 1.05 0.86–1.29 0.635 1.14 0.92–1.40 0.223
NR 21 12.1 127 20.1 1.15 0.91–1.46 0.247 0.511 1.22 0.96–1.55 0.111 0.245
HIV viral load at baseline
(HIV-1 RNA copies/mL)
o 10 000 33 19.1 122 19.3
10 000–50 000 31 17.9 138 21.8 1.01 0.80–1.30 0.906 1.07 0.83–1.38 0.582
50 0001 87 50.3 246 38.9 0.95 0.76–1.18 0.632 0.97 0.77–1.22 0.792
NR 22 12.7 126 19.9 1.12 0.87–1.43 0.386 0.541 1.11 0.86–1.43 0.423 0.998
Previous ADI
No 156 90.2 532 84.2
Yes 17 9.8 100 15.8 1.25 1.01–1.55 0.041 0.041 1.12 0.90–1.39 0.293 0.293
Previous ART
None 133 76.9 399 63.1
Mono 9 5.2 53 8.4 1.27 0.95–1.69 0.106 1.22 0.92–1.63 0.171
Double 31 17.9 180 28.5 1.27 1.06–1.51 0.009 0.006 1.25 1.05–1.49 0.014 0.011
Drug class combination
PI-based HAART
(excludes NNRTI) 52 30.1 370 58.5
(excludes PI) 115 66.5 230 36.4 0.63 0.54–0.75 0.000 0.64 0.54–0.75 0.000
NNRTI/PI HAART combination 6 3.5 32 5.1 0.93 0.65–1.33 0.685 0.000 0.89 0.62–1.28 0.522 0.000
Year initiated
1997 31 17.9 300 47.5
1998 43 24.9 155 24.5 0.81 0.67–0.99 0.035 0.89 0.73–1.09 0.260
1999 35 20.2 92 14.6 0.93 0.73–1.18 0.539 1.07 0.84–1.37 0.576
2000 30 17.3 53 8.4 0.86 0.64–1.16 0.334 1.03 0.76–1.40 0.832
2001 15 8.7 24 3.8 1.05 0.69–1.59 0.835 1.18 0.78–1.80 0.434
2002 19 11 8 1.3 0.68 0.34–1.38 0.290 0.297 0.74 0.37–1.51 0.413 0.763
*P-values reported for test of homogeneity in nominal covariates and test for trend in ordinal covariates. Patients with data not recorded were not included
when testing trend.
Co-infection status: HBV and HCV negative (HBV /HCV ); HBV positive only (HBV1 /HCV ); HCV positive only (HBV–/HCV1 ); and co-infection with
HBV and HCV (HBV1 /HCV1 ).
HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; MSM, men who have sex with men; NR, not recorded; ADI, AIDS-
defining illness; ART, antiretroviral therapy; HAART, highly active antiretroviral therapy; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease
inhibitor.
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In this study, factors that were independently associated
with an increased rate of change of combination anti-
retroviral treatment were a previous diagnosis with an
AIDS-defining illness (34% faster), and prior exposure to
double combination antiretroviral therapy compared with
being previously naı¨ve (29% faster). Combinations that
included a NNRTI had a 30% slower rate of combination
treatment change compared with combinations that
included a PI. Co-infection with HBV and/or HCV was
not found to be significantly associated with the rate of
combination antiretroviral treatment change. Other factors,
such as age, sex, exposure category, CD4 count and viral
load at baseline, were also not significantly associated with
the rate of combination antiretroviral treatment change.
Although calendar year was significantly associated with
the overall rate of combination change, it was not
significantly associated with the first combination change.
Co-infection status was also not associated with stopping
treatment combinations that included either nevirapine or
efavirenz.
Our findings that HBV and/or HCV co-infection was not
associated with the rate of change of combination
antiretroviral treatment are supported by several other
studies. Greub et al. [8] found that the probability of
changing antiretroviral treatment was not associated with
HCV status, but was associated with AIDS at baseline, RNA
at baseline, duration of therapy and sex. Sulkowski et al.
[15] found that HCV co-infection did not alter virological
or immunological response to HAART.
In our analysis, patients who were receiving a regimen
including a NNRTI had a slower rate of change of
antiretroviral treatment than those receiving a PI. Whether
this was a result of better tolerability of these compounds
or fewer adverse events, such as toxicities, is unknown.
Calendar year was also shown to be associated with the rate
of combination change overall, more recent time periods
having significantly slower rates of change compared with
earlier time periods. Such an association was not seen in
time to first combination change post-HAART. This is
probably a result of the fact that most patients in this
cohort had commenced their very first HAART combina-
tion before the year 2000.
In the AHOD we also saw that co-infection status was not
associated with stopping either nevirapine or efavirenz. In
a study with similar demographics to the AHOD, where
patients were predominantly homosexual men, no associa-
tion was found between HBV and HCV infection and
hepatotoxicity caused by NNRTI use [11]. Sulkowski et al.
[10] analysed the outcome of NNRTI-containing HAART in
an HIV hospital clinic and also found that the majority of
their patients did not develop hepatotoxicity; however,
among those who did, it was more common if they were
also concurrently using a PI, or if they had HCV or HBC co-
infection.
There are several limitations to our study. Firstly,
recruitment to the AHOD commenced in June 1999, but a
large proportion of the data concerning antiretroviral
treatment, HIV disease stage, and HBV and HCV status was
collected retrospectively. Hence, the analysis presented in
this study is based on retrospective as well as prospective
data. Secondly, HBV and HCV status data were not
collected in a standardized format, but rather by clinician
reporting. HCV status was based on antibody rather than
HCV RNA testing, and HBV status, in some instances, may
have been based on a single HBsAg antibody result.
However, it could be expected that the large majority had
chronic HBV and HCV infection. Among the HCV-infected
patients, approximately 80% had chronic HCV infection
based on the limited HCV RNA testing. Furthermore, no
assessment of liver disease outcomes was conducted.
Whether the study was sufficiently powered to detect a
difference in the rates of change amongst the different co-
infection groups is also questionable, given the wide
confidence limits for each of these groups. A post hoc
power analysis determined that at least 35 patients needed
to be co-infected with HBV and HCV in order for the
difference detected in this study to be significant. In this
population, only 15 patients, less than half the required
number, were co-infected with both HBV and HCV.
Finally, in this analysis it was not possible to assess
whether treatment changes were caused by toxicity,
virological failure or other factors. Ascribing reasons for
treatment change is difficult, with toxicity, adherence and
virological efficacy closely linked. A strength of our
analysis is that all treatment changes were included, based
on the assumption that more changes, for whatever reason,
represent a poorer outcome than fewer changes. This
overall rate of change endpoint is also quite a sensitive
outcome [12].
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Fig. 2 Time to stopping nevirapine or efavirenz, by hepatitis B and C
virus co-infection status.
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Our analyses, both in this paper and in previous work [4],
suggest that HIV/HCV and HIV/HBV co-infection are not
serious impediments to a patient’s treatment for HIV
infection. One feature of the HIV epidemic in Australia is
that HIV transmission is overwhelmingly through male
homosexual content, with very few people living with HIV
actually injecting illicit drugs [16]. Whether the poorer
outcomes, both in terms of response to treatment as well as
in the long-term, as seen in co-infected patients in other
studies, reflect ongoing active injecting drug use rather
than HCV or HBV co-infection deserves more thorough
investigation.
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Appendix 1: The Australian HIV
Observational Database
Asterisks indicate Steering Committee members.
New South Wales: R. Goodman and M. Gotowski, Bligh
Street Clinic, Tamworth; D. Couldwell and L. Lewis, Blue
Mountains Sexual Health and HIV Clinic, Katoomba; D.
Austin, M. Block, D. Quan and A. Gowers, Holdsworth
House General Practice, Darlinghurst; K. Brown and N.
Skobalj, Illawarra Sexual Health, Warrawong; C. O’Connor
and M. Mitchell, Livingstone Road Sexual Health Centre,
Marrickville; D. Templeton, Macquarie Sexual Health
Centre, Dubbo; M. T. Liang, Nepean Sexual Health and
HIV Clinic, Penrith; D. Allen, B. Strazdinis and B. Mulhall*,
Holden Clinic, Gosford; D. Smith, K. Mutimer and J.
Armishaw, Sexual Health & AIDS Services (SHAIDS),
Lismore; D. Cooper, A. Carr and M. Lacey, St Vincents
Hospital, Sydney; C. Pell and R. Rohrsheim, Sydney Sexual
Health Centre, Sydney; R. Finlayson and R. Richardson,
Taylor Square Private Clinic, Darlinghurst; D. Ellis, The
Medical and Vein Centre, Coffs Harbour; D. Baker*, J. Kidd,
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R. McFarlane and R. Vale, 407 Bourke Street, Surry Hill; P.
Canavan*, M. Law*, K. Petoumenos* and D. Smith*,
National Centre in HIV Epidemiology and Clinical Re-
search, Darlinghurst.
Northern Territory: S. Huffam, J. Savage, S. Morgan and
P. Knibbs, Communicable Disease Centre, Royal Darwin
Hospital, Darwin.
South Australia: G. Rogers, S. Markinson, C. Sullivan,
F. Downey, M. Curry, J. Oddy and J. Thompson, The
Care and Prevention Programme, Adelaide University,
Adelaide.
Queensland: H. Ree and H. Magon, AIDS Medical Unit,
Brisbane; D. Sowden and A. Walker, Blackall Terrace
Specialist Centre, Blackall Terrace; D. Orth, G. Lister and D.
Youds, Gladstone Road Medical Centre, Highgate Hill; J.
Chuah, R. James, W. Fankhauser and B. Dickson, Gold
Coast Sexual Health Clinic, Miami; D. Bradford, J. Leamy
and C. D’arcy Evans, Sexual Health Program, Cairns Base
Hospital, Cairns.
Victoria: T. Reid and J. Laing, Melbourne Sexual Health
Centre, Carlton; I. Woolley, T. Korman, A. Padiglione and K.
Visvanathan, Monash Medical Centre, Clayton; N. Roth*, B.
Eu, S. Strecker, D. Russell and H. Wood, Prahran Market
Clinic, South Yarra; A. Mijch*, J. Hoy, A. Pierce, C.
McCormack and K. Watson, The Alfred Hospital, Prahran;
J. Anderson,* R. Moore, D. Russell, G. McGovern, R.
McNair, K. Lowe and J. Bal, The Carlton Clinic, Carlton; N.
Medland, The Centre Clinic, St Kilda, National Association
of People with AIDS (NAPWA), East Brunswick.
Western Australia: S. Mallal*, M. French, J. Skett and C.
Moore, Department of Clinical Immunology, Royal Perth
Hospital, Perth.
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